168 related articles for article (PubMed ID: 24552987)
1. Immunologic biomarkers in prostate cancer: the AE37 paradigm.
Baxevanis CN; Papamichail M; Perez SA
Hum Vaccin Immunother; 2014; 10(5):1244-7. PubMed ID: 24552987
[TBL] [Abstract][Full Text] [Related]
2. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
[TBL] [Abstract][Full Text] [Related]
3. A pilot study in prostate cancer patients treated with the AE37 Ii-key-HER-2/neu polypeptide vaccine suggests that HLA-A*24 and HLA-DRB1*11 alleles may be prognostic and predictive biomarkers for clinical benefit.
Anastasopoulou EA; Voutsas IF; Keramitsoglou T; Gouttefangeas C; Kalbacher H; Thanos A; Papamichail M; Perez SA; Baxevanis CN
Cancer Immunol Immunother; 2015 Sep; 64(9):1123-36. PubMed ID: 26026288
[TBL] [Abstract][Full Text] [Related]
4. AE37 peptide vaccination in prostate cancer: a 4-year immunological assessment updates on a phase I trial.
Perez SA; Anastasopoulou EA; Tzonis P; Gouttefangeas C; Kalbacher H; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2013 Oct; 62(10):1599-608. PubMed ID: 23934022
[TBL] [Abstract][Full Text] [Related]
5. Results from a phase I clinical study of the novel Ii-Key/HER-2/neu(776-790) hybrid peptide vaccine in patients with prostate cancer.
Perez SA; Kallinteris NL; Bisias S; Tzonis PK; Georgakopoulou K; Varla-Leftherioti M; Papamichail M; Thanos A; von Hofe E; Baxevanis CN
Clin Cancer Res; 2010 Jul; 16(13):3495-506. PubMed ID: 20466887
[TBL] [Abstract][Full Text] [Related]
6. AE37 peptide vaccination in prostate cancer: identification of biomarkers in the context of prognosis and prediction.
Perez SA; Anastasopoulou EA; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2014 Nov; 63(11):1141-50. PubMed ID: 25052849
[TBL] [Abstract][Full Text] [Related]
7. AE37: a HER2-targeted vaccine for the prevention of breast cancer recurrence.
McCarthy PM; Clifton GT; Vreeland TJ; Adams AM; O'Shea AE; Peoples GE
Expert Opin Investig Drugs; 2021 Jan; 30(1):5-11. PubMed ID: 33191799
[TBL] [Abstract][Full Text] [Related]
8. Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium.
Curigliano G; Criscitiello C; Esposito A; Fumagalli L; Gelao L; Locatelli M; Minchella I; Goldhirsch A
Breast; 2013 Aug; 22 Suppl 2():S96-9. PubMed ID: 24074802
[TBL] [Abstract][Full Text] [Related]
9. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
Holmes JP; Benavides LC; Gates JD; Carmichael MG; Hueman MT; Mittendorf EA; Murray JL; Amin A; Craig D; von Hofe E; Ponniah S; Peoples GE
J Clin Oncol; 2008 Jul; 26(20):3426-33. PubMed ID: 18612158
[TBL] [Abstract][Full Text] [Related]
10. Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer.
Disis ML; Wallace DR; Gooley TA; Dang Y; Slota M; Lu H; Coveler AL; Childs JS; Higgins DM; Fintak PA; dela Rosa C; Tietje K; Link J; Waisman J; Salazar LG
J Clin Oncol; 2009 Oct; 27(28):4685-92. PubMed ID: 19720923
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination.
Johnson LE; Olson BM; McNeel DG
J Immunother Cancer; 2017 Jul; 5(1):56. PubMed ID: 28716080
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients.
Hueman MT; Dehqanzada ZA; Novak TE; Gurney JM; Woll MM; Ryan GB; Storrer CE; Fisher C; McLeod DG; Ioannides CG; Ponniah S; Peoples GE
Clin Cancer Res; 2005 Oct; 11(20):7470-9. PubMed ID: 16243821
[TBL] [Abstract][Full Text] [Related]
13. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
14. MHC class II tetramer analyses in AE37-vaccinated prostate cancer patients reveal vaccine-specific polyfunctional and long-lasting CD4(+) T-cells.
Anastasopoulou EA; Voutsas IF; Papamichail M; Baxevanis CN; Perez SA
Oncoimmunology; 2016 Jul; 5(7):e1178439. PubMed ID: 27622033
[TBL] [Abstract][Full Text] [Related]
15. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.
Knutson KL; Schiffman K; Cheever MA; Disis ML
Clin Cancer Res; 2002 May; 8(5):1014-8. PubMed ID: 12006513
[TBL] [Abstract][Full Text] [Related]
16. AE37: a novel T-cell-eliciting vaccine for breast cancer.
Sears AK; Perez SA; Clifton GT; Benavides LC; Gates JD; Clive KS; Holmes JP; Shumway NM; Van Echo DC; Carmichael MG; Ponniah S; Baxevanis CN; Mittendorf EA; Papamichail M; Peoples GE
Expert Opin Biol Ther; 2011 Nov; 11(11):1543-50. PubMed ID: 21895539
[TBL] [Abstract][Full Text] [Related]
17. Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer.
Miller AM; Ozenci V; Kiessling R; Pisa P
J Immunother; 2005; 28(4):389-95. PubMed ID: 16000958
[TBL] [Abstract][Full Text] [Related]
18. CD4+ T cells in antitumor immunity: utility of an li-key HER2/neu hybrid peptide vaccine (AE37).
Mittendorf EA; Holmes JP; Murray JL; von Hofe E; Peoples GE
Expert Opin Biol Ther; 2009 Jan; 9(1):71-8. PubMed ID: 19063694
[TBL] [Abstract][Full Text] [Related]
19. Vaccination against the HER-2/neu oncogenic protein.
Bernhard H; Salazar L; Schiffman K; Smorlesi A; Schmidt B; Knutson KL; Disis ML
Endocr Relat Cancer; 2002 Mar; 9(1):33-44. PubMed ID: 11914181
[TBL] [Abstract][Full Text] [Related]
20. Molecular insights into the development of T cell-based immunotherapy for prostate cancer.
Dong B; Minze LJ; Xue W; Chen W
Expert Rev Clin Immunol; 2014 Nov; 10(11):1547-57. PubMed ID: 25259804
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
